PF-03550096 explained

PF-03550096 is a drug that acts as a potent agonist for the CB₂ cannabinoid receptor, with good selectivity over CB₁ having K_i values of 7nM at CB₂ and 1500nM at CB₁. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,^[1] but has only progressed to animal studies.^[2]

See also

• A-PBITMO
• AB-FUBINACA
• AB-PINACA

Notes and References

1. WO . 2008032164 . 20 March 2008 . Benzimidazolone Derivatives . Ando K, et al . Pfizer Products Inc. .
2. Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H . Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity . Journal of Pharmacological Sciences . 106 . 2 . 219–24 . February 2008 . 18270474 . 10.1254/jphs.FP0071599 . free .